These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 25559771)

  • 1. Relative efficacy and safety of simeprevir and telaprevir in treatment-naïve hepatitis C-infected patients in a Japanese population: A Bayesian network meta-analysis.
    Quigley JM; Bryden PA; Scott DA; Kuwabara H; Cerri K
    Hepatol Res; 2015 Oct; 45(10):E89-98. PubMed ID: 25559771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of peg-interferon, ribavirin plus telaprevir vs simeprevir by propensity score matching.
    Fujii H; Nishimura T; Umemura A; Nishikawa T; Yamaguchi K; Moriguchi M; Sumida Y; Mitsuyoshi H; Yokomizo C; Tanaka S; Ishikawa H; Nishioji K; Kimura H; Takami S; Nagao Y; Takeuchi T; Shima T; Sawa Y; Minami M; Yasui K; Itoh Y
    World J Hepatol; 2015 Dec; 7(28):2841-8. PubMed ID: 26668696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report.
    Kawaoka T; Imamura M; Kan H; Fujino H; Fukuhara T; Kobayashi T; Honda Y; Naeshiro N; Hiramatsu A; Tsuge M; Hayes CN; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Tashiro H; Ohdan H; Chayama K
    Transplant Proc; 2015 Apr; 47(3):809-14. PubMed ID: 25891736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan.
    Kuwabara H; Westerhout K; Treur M; Cerri K; Mahlich J; Yatsuhashi H
    J Med Econ; 2015; 18(7):502-11. PubMed ID: 25763827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service.
    Westerhout K; Treur M; Mehnert A; Pascoe K; Ladha I; Belsey J
    J Med Econ; 2015; 18(10):838-49. PubMed ID: 25903830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C.
    Yamagiwa S; Ishikawa T; Waguri N; Sugitani S; Wakabayashi H; Ohkoshi S; Tsukishiro T; Takahashi T; Watanabe T; Terai S
    World J Hepatol; 2017 Feb; 9(5):252-262. PubMed ID: 28261382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.
    Pungpapong S; Aqel BA; Koning L; Murphy JL; Henry TM; Ryland KL; Yataco ML; Satyanarayana R; Rosser BG; Vargas HE; Charlton MR; Keaveny AP
    Liver Transpl; 2013 Jul; 19(7):690-700. PubMed ID: 23696372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of telaprevir with pegylated interferon α-2a and ribavirin in Japanese patients.
    Kumada H; Suzuki F; Kamiya N; Orihashi M; Nakayasu Y; Yamada I
    Hepatol Res; 2017 May; 47(6):514-521. PubMed ID: 27062488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.
    Kumada H; Hayashi N; Izumi N; Okanoue T; Tsubouchi H; Yatsuhashi H; Kato M; Rito K; Komada Y; Seto C; Goto S
    Hepatol Res; 2015 May; 45(5):501-13. PubMed ID: 24961662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
    Taieb V; Pacou M; Ho S; Pettré S; Van Sanden S; Pisini M; Ustianowski A; Mehnert A
    J Med Econ; 2015; 18(10):787-96. PubMed ID: 25934147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Indirect comparison of the antiviral efficacy of peginterferon alpha 2a plus ribavirin used with or without simeprevir in genotype 4 hepatitis C virus infection, where common comparator study arms are lacking: a special application of the matching adjusted indirect comparison methodology.
    Van Sanden S; Pisini M; Duchesne I; Mehnert A; Belsey J
    Curr Med Res Opin; 2016; 32(1):147-54. PubMed ID: 26455472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
    Flisiak R; Kawazoe S; Znoyko O; Assy N; Gadano A; Kao JH; Lee KS; Zwirtes R; Portsmouth S; Dong Y; Xu D; Kumada H; Srinivasan S
    J Interferon Cytokine Res; 2016 Nov; 36(11):635-643. PubMed ID: 27327078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
    Sugimoto K; Kim SR; Kim SK; Imoto S; Tohyama M; Kim KI; Ohtani A; Hatae T; Yano Y; Kudo M; Hayashi Y
    Oncology; 2015; 89 Suppl 2():42-6. PubMed ID: 26584035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
    Flisiak R; Shiffman M; Arenas J; Cheinquer H; Nikitin I; Dong Y; Rana K; Srinivasan S
    PLoS One; 2016; 11(10):e0164563. PubMed ID: 27749900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of telaprevir with natural human interferon-β and ribavirin in Japanese chronic hepatitis C patients with depression.
    Kumada H; Mochida S; Nakamuta M; Suzuki F; Yagi T; Takasaki R; Okai M; Kamiya N; Okada Y; Hirota S; Orihashi M; Ochi M; Chayama K
    Hepatol Res; 2018 Feb; 48(2):184-192. PubMed ID: 28497489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study.
    Suda G; Ito J; Nagasaka A; Yamamoto Y; Furuya K; Okamoto M; Terashita K; Kobayashi T; Tsunematsu I; Yoshida J; Meguro T; Ohara M; Kawagishi N; Kimura M; Umemura M; Izumi T; Tsukuda Y; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Sakamoto N;
    Hepatol Res; 2018 Feb; 48(3):E146-E154. PubMed ID: 28722780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Viral Response Predicts the Efficacy of Antiviral Triple Therapy with Simeprevir, Peg-Interferon and Ribavirin in Patients Infected with Hepatitis C Virus Genotype 1.
    Nishida N; Iwanishi M; Minami T; Chishina H; Arizumi T; Takita M; Kitai S; Yada N; Ida H; Hagiwara S; Minami Y; Ueshima K; Sakurai T; Kitano M; Kudo M
    Dig Dis; 2015 Oct; 33(6):708-14. PubMed ID: 26488400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.
    Morishita N; Hiramatsu N; Oze T; Urabe A; Tahata Y; Yamada R; Yakushijin T; Hosui A; Iio S; Yamada A; Hagiwara H; Mita E; Yamada Y; Ito T; Inada M; Katayama K; Yabuuchi I; Imai Y; Hikita H; Sakamori R; Yoshida Y; Tatsumi T; Hayashi N; Takehara T
    Hepatol Res; 2017 Jul; 47(8):773-782. PubMed ID: 27593967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.
    Cure S; Diels J; Gavart S; Bianic F; Jones E
    Curr Med Res Opin; 2012 Nov; 28(11):1841-56. PubMed ID: 23016967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs.
    Hartman J; Bichoupan K; Patel N; Chekuri S; Harty A; Dieterich D; Perumalswami P; Branch AD
    World J Gastroenterol; 2015 Nov; 21(43):12430-8. PubMed ID: 26604650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.